PKU HealthCare (SZ:000788) 2 1 Shi Ji Jing Ji Bao Dao·2025-10-30 14:48Core Viewpoint - The recent criminal detention of Xu Xiren, the chairman and president of Beijing University Pharmaceutical, has raised concerns about the company's leadership stability and operational continuity [1][6]. Company Leadership Changes - Xu Xiren was temporarily unable to perform his duties due to personal reasons, leading to the delegation of his responsibilities to other executives [1]. - Following the announcement of his criminal detention, the company confirmed that it is unaware of the investigation's progress and has made arrangements for ongoing operations [1][6]. - The company has experienced significant management turnover in recent months, with multiple resignations due to personal reasons [3][5]. Business Operations and Financial Performance - Beijing University Pharmaceutical positions itself as an integrated pharmaceutical technology enterprise, focusing on the research, production, and sale of chemical drug formulations [3]. - The company has undergone a significant change in control, with the actual control shifting away from Peking University, and is in the process of rebranding to reflect this change [6][7]. - The company is facing potential revenue declines due to the termination of a long-term service contract with Peking University International Hospital, which could result in a revenue decrease of approximately 600 million yuan (29.13% of the latest audited revenue) and a net profit decrease of around 40 million yuan (28.99% of the latest audited net profit) [7]. - Financial results indicate a revenue decline of 6.10% year-on-year for 2024, with total revenue of 2.06 billion yuan, while net profit increased by 211.10% to 138 million yuan [7]. - The third-quarter report showed a revenue drop of 19.76% year-on-year, totaling 1.231 billion yuan, with a net profit of 136 million yuan, reflecting a 4.31% increase [7].